5fas: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
==OXA-48 in complex with FPI-1523==
==OXA-48 in complex with FPI-1523==
<StructureSection load='5fas' size='340' side='right' caption='[[5fas]], [[Resolution|resolution]] 1.74&Aring;' scene=''>
<StructureSection load='5fas' size='340' side='right'caption='[[5fas]], [[Resolution|resolution]] 1.74&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[5fas]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FAS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FAS FirstGlance]. <br>
<table><tr><td colspan='2'>[[5fas]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Klebsiella_pneumoniae Klebsiella pneumoniae]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FAS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5FAS FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5VR:[[(3~{R},6~{S})-6-(ACETAMIDOCARBAMOYL)-1-METHANOYL-PIPERIDIN-3-YL]AMINO]+HYDROGEN+SULFATE'>5VR</scene>, <scene name='pdbligand=CD:CADMIUM+ION'>CD</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CO:COBALT+(II)+ION'>CO</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.74&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5fao|5fao]], [[5fa7|5fa7]], [[5fap|5fap]], [[5faq|5faq]], [[5fat|5fat]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5VR:[[(3~{R},6~{S})-6-(ACETAMIDOCARBAMOYL)-1-METHANOYL-PIPERIDIN-3-YL]AMINO]+HYDROGEN+SULFATE'>5VR</scene>, <scene name='pdbligand=CD:CADMIUM+ION'>CD</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CO:COBALT+(II)+ION'>CO</scene></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Beta-lactamase Beta-lactamase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.5.2.6 3.5.2.6] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5fas FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fas OCA], [https://pdbe.org/5fas PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5fas RCSB], [https://www.ebi.ac.uk/pdbsum/5fas PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5fas ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5fas FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fas OCA], [http://pdbe.org/5fas PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fas RCSB], [http://www.ebi.ac.uk/pdbsum/5fas PDBsum]</span></td></tr>
</table>
</table>
== Function ==
[https://www.uniprot.org/uniprot/Q6XEC0_KLEPN Q6XEC0_KLEPN]
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 17: Line 19:
</div>
</div>
<div class="pdbe-citations 5fas" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 5fas" style="background-color:#fffaf0;"></div>
==See Also==
*[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Beta-lactamase]]
[[Category: Klebsiella pneumoniae]]
[[Category: Alexander, A N]]
[[Category: Large Structures]]
[[Category: Asli, A]]
[[Category: Alexander AN]]
[[Category: Brouillette, E]]
[[Category: Asli A]]
[[Category: Brown, E D]]
[[Category: Brouillette E]]
[[Category: French, S]]
[[Category: Brown ED]]
[[Category: King, A M]]
[[Category: French S]]
[[Category: King, D T]]
[[Category: King AM]]
[[Category: Maiti, S N]]
[[Category: King DT]]
[[Category: Malouin, F]]
[[Category: Maiti SN]]
[[Category: Parr, T R]]
[[Category: Malouin F]]
[[Category: Strynadka, N C.J]]
[[Category: Parr TR]]
[[Category: Vuckovic, M]]
[[Category: Strynadka NCJ]]
[[Category: Wright, G D]]
[[Category: Vuckovic M]]
[[Category: Hydrolase-hydrolase inhibitor complex]]
[[Category: Wright GD]]

Latest revision as of 09:44, 19 July 2023

OXA-48 in complex with FPI-1523OXA-48 in complex with FPI-1523

Structural highlights

5fas is a 2 chain structure with sequence from Klebsiella pneumoniae. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.74Å
Ligands:, , ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

Q6XEC0_KLEPN

Publication Abstract from PubMed

Avibactam is a diazabicyclooctane beta-lactamase inhibitor possessing outstanding but incomplete efficacy against multidrug-resistant Gram-negative pathogens in combination with beta-lactam antibiotics. Significant pharmaceutical investment in generating derivatives of avibactam warrants a thorough characterization of their activity. We show here through structural and kinetic analysis that select diazabicyclooctane derivatives display effective but varied inhibition of two clinically important beta-lactamases (CTX-M-15 and OXA-48). Furthermore, these derivatives exhibit considerable antimicrobial activity (MIC </= 2 mug/mL) against clinical isolates of Pseudomonas aeruginosa, Escherichia coli, and Enterobacter spp. Imaging of cell phenotype along with structural and biochemical experiments unambiguously demonstrate that this activity, in E. coli, is a result of targeting penicillin-binding protein 2. Our results suggest that structure-activity relationship studies for the purpose of drug discovery must consider both beta-lactamases and penicillin-binding proteins as targets. We believe that this approach will yield next-generation combination or monotherapies with an expanded spectrum of activity against currently untreatable Gram-negative pathogens.

Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-beta-Lactamases and Penicillin-Binding Proteins.,King AM, King DT, French S, Brouillette E, Asli A, Alexander JA, Vuckovic M, Maiti SN, Parr TR Jr, Brown ED, Malouin F, Strynadka NC, Wright GD ACS Chem Biol. 2016 Jan 14. PMID:26731698[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. King AM, King DT, French S, Brouillette E, Asli A, Alexander JA, Vuckovic M, Maiti SN, Parr TR Jr, Brown ED, Malouin F, Strynadka NC, Wright GD. Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-beta-Lactamases and Penicillin-Binding Proteins. ACS Chem Biol. 2016 Jan 14. PMID:26731698 doi:http://dx.doi.org/10.1021/acschembio.5b00944

5fas, resolution 1.74Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA